Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833834 | 0.88 | MEN1 (0.52) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL25276282 | 0.84 | APEX1 (0.59) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL28357637 | 0.84 | MEN1 (0.51) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL3203044 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL8111309 | 0.78 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL18171779 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL17772674 | 0.77 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL7224645 | 0.77 | ALDH1A1 (0.88) | ALDH1A1MEN1KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL25232659 | 0.76 | MEN1 (0.43) | ALDH1A1MEN1KMT2AGAAL3MBTL1 | |
| SCHEMBL639643 | 0.75 | MEN1 (0.67) | ALDH1A1MEN1KMT2AGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665728-A1 | DDR1 AND DDR2 INHIBITORS HAVING A DIHYDROBENZIMIDAZOLONE CORE | Redx Pharma Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4665729-A1 | DDR1 AND DDR2 INHIBITORS HAVING A DIHYDROBENZIMIDAZOLONE CORE | Redx Pharma Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4577543-A1 | PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER | Redx Pharma Limited (GB) | 2025-07-02 | — | — | EP | disclosed |
| CN-119768403-A | Pyridopyrazoles as DDR inhibitors for the treatment of fibrotic disorders and cancer | 莱德克斯制药有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-115836054-B | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024170907-A1 | DDR1 AND DDR2 INHIBITORS HAVING A DIHYDROBENZIMIDAZOLONE CORE | REDX PHARMA LIMITED (GB) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024170909-A1 | DDR1 AND DDR2 INHIBITORS HAVING A DIHYDROBENZIMIDAZOLONE CORE | REDX PHARMA LIMITED (GB) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024042316-A1 | PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER | REDX PHARMA PLC. (GB) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042316-A1 | PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER | REDX PHARMA PLC. (GB) | 2024-02-29 | — | — | WO | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | ALDH1A1 471/4885MEN1 1034/4885KMT2A 3013/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | ALDH1A1 471/4885MEN1 1034/4885KMT2A 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.